iCAD (NASDAQ:ICAD – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect iCAD to post earnings of ($0.05) per share and revenue of $4.72 million for the quarter.
iCAD Stock Down 2.1 %
ICAD opened at $2.36 on Tuesday. The firm has a market capitalization of $62.63 million, a P/E ratio of -18.15 and a beta of 1.47. The stock’s 50 day moving average price is $2.56 and its two-hundred day moving average price is $2.00. iCAD has a 12-month low of $1.18 and a 12-month high of $3.78.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, February 20th.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
- Five stocks we like better than iCAD
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How Can Investors Benefit From After-Hours Trading
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
